The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cardiac safety of trabectedin monotherapy and in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Lilly; Merck Serono; Morphotek; PharmaMar; TRACON Pharma
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Thomas J. Herzog
Leadership - GOG Partners
Consulting or Advisory Role - AstraZeneca; Caris MPI; Clovis Oncology; GlaxoSmithKline; Johnson & Johnson; Roche/Genentech
 
Shreyaskumar Patel
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Daiichi Sankyo; Epizyme; Immune Design; Janssen; Lilly; MaxiVax ; Novartis
Research Funding - Blueprint Medicines (Inst)
 
Margaret von Mehren
Honoraria - Pfizer
Consulting or Advisory Role - deciphera; Exelixis
Research Funding - ADCO (Inst); Arog (Inst); ArQule; Blueprint Medicines (Inst); Deciphera (Inst); Genmab (Inst); Gradalis (Inst); Lilly (Inst); Novartis (Inst); Springworks Therapeutics (Inst)
Travel, Accommodations, Expenses - Deciphera; Deciphera; NCCN
Other Relationship - NCCN
 
Scott Schuetze
Research Funding - Adaptimmune (Inst); Amgen (Inst); Blueprint Medicines (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Blueprint Medicines
 
Brian Andrew Van Tine
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; Bayer; Caris Life Sciences; CytRx Corporation; Daiichi Sankyo; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Johnson & Johnson; Lilly/ImClone; Novartis; Pfizer; Plexxikon; Threshold Pharmaceuticals
Speakers' Bureau - Adaptimmune; Caris Life Sciences; GlaxoSmithKline; Johnson & Johnson; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Lilly
 
Robert L. Coleman
Consulting or Advisory Role - Abbvie; Abbvie/Stemcentrx; Agenus; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Genentech/Roche; Genmab; Immunogen; Novocure; Oncolytics; OncoMed; OncoSec; Sotio; Tesaro
Research Funding - Abbott/AbbVie; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merck; OncoMed; Roche/Genentech
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Spyridon Triantos
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Peter Hu
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Waleed Shalaby
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Tracy McGowan
Employment - Janssen Scientific Affairs
Stock and Other Ownership Interests - Johnson & Johnson
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Agenus; Amgen; AstraZeneca; ChemoCare; ChemoID; Clovis Oncology; Conjupro Biotherapeutics; Eisai; Geistlich Pharma; Genmab; Immunogen; Immunomedics; Incyte; Janssen; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; OncoQuest; Perthera; Pfizer; Precision Oncology; Puma Biotechnology; Roche/Genentech; Samumed; Takeda; Tesaro; VBL Therapeutics
Consulting or Advisory Role - Abbvie; Advaxis; Amgen; AstraZeneca; Cerulean Pharma; ChemoCare; ChemoID; Clovis Oncology; Eisai; Geistlich Pharma; Immunogen; Incyte; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; OncoMed; OncoSec; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Samumed; Takeda; Tesaro; VBL Therapeutics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Janssen; Roche/Genentech; Tesaro
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
George D. Demetri
Leadership - Blueprint Medicines; Merrimack; Translate BIO
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Champions Oncology; Erasca, Inc; G1 Therapeutics; Merrimack; Relay Therapeutics; Translate BIO
Consulting or Advisory Role - Acrivon Therapeutics; Adaptimmune; Arsenal Capital; Bayer; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Epizyme; G1 Therapeutics; ICON Clinical Research; Ignyta; Janssen Oncology; Loxo; Medscape; Mirati Therapeutics; MJH Associates; Novartis; Pfizer; PharmaMar; Polaris; Relay Therapeutics; Roche/Genentech; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - AbbVie (Inst); Abbvie (Inst); Adaptimmune (Inst); Bayer (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Janssen Oncology (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis
Expert Testimony - Epizyme